Additionally, ICIs targeting PD-1, PD-L1, or CTLA4 have enabled the possibility of long-term survival in patients with tumors such as melanoma, HCC, breast cancer, and colorectal cancer (47, 48). This evidence concerns the gene CTLA4 and breast carcinoma.